VANI — Vivani Medical Share News
0.000.00%
Last trade - 00:00Vivani Medical Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Vivani Medical And Okava Expand Collaboration To Develop Okv-119 For Dogs, Targeting Metabolic Health And Longevity
Brief: Vivani Medical Announces $8.25M Private Placement Equity Financing
Brief: Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing
Brief: Vivani Medical Achieves First Implant And Full Enrollment In The First-In-Human Clinical Trial Of GLP-1 Implant NPM-115 In Obese Or Overweight Adults
Brief: Vivani Medical intends to spin off brain implants division
Brief: Vivani Medical Receives Regulatory Approval To Initiate First In Human Clinical Trial With Glp-1 Implant In Obese And Overweight Individuals In Australia
Vivani Medical Inc expected to post a loss of 12 cents a share - Earnings Preview
Vivani Medical up on plans to begin first human study for obesity implant
Brief: Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115
U.S. STOCKS ON THE MOVE-ACI Worldwide, enCore Energy, Adobe
U.S. STOCKS ON THE MOVE-Williams-Sonoma, ACI Worldwide, enCore Energy
U.S. STOCKS ON THE MOVE-Vivani, Vanda, Sarepta
Vivani jumps as US FDA lifts clinical hold on trial for diabetes treatment implant
Brief: Vivani Medical Announces FDA Clears Investigational New Drug Application And Lifts Clinical Hold For NPM-119, A Miniature Long-Term Subdermal Glp-1 Drug Implant
Brief: Vivani Medical Announces Publication Of Positive Weight Loss Data Supporting Potential Veterinary Use Of Okv-119 Miniature, Long-Term Glp-1 Implant
Vivani Medical Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Vivani Medical Files For Mixed Shelf Of Up To $300 Mln – SEC Filing
Vivani Medical Inc reports results for the quarter ended in December - Earnings Summary